ArticlePharmaceuticals (Basel, Switzerland)2022

Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio.

Jeng-Shiuan Tsai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.